HDAC9 and cancer: HDAC inhibitors are proving to be an exciting therapeutic approach to cancer and some HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA), have entered into clinical trials6, 9, 10.